Tecartus Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tecartus market research report is one of a series of new reports that provides tecartus market statistics, including tecartus industry global market size, regional shares, competitors with a tecartus market share, detailed tecartus market segments, market trends and opportunities, and any further data you may need to thrive in the tecartus industry. This tecartus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing global incidence of hematologic cancers, rising adoption of Car T-cell therapies, expanding healthcare infrastructure in emerging markets, rising healthcare awareness and education, and expansion of reimbursement policies for Car T-cell therapies. Major trends in the forecast period include increasing collaboration between biotech and pharmaceutical companies, the development of next-generation Car T-cell therapies, the integration of artificial intelligence in treatment optimization, advancements in Car T-cell therapy technologies, and advancements in gene editing technologies.

The increasing prevalence of hematologic cancers is expected to drive the growth of the tecartus market. Hematologic cancers are malignancies that arise in blood-forming tissues such as the bone marrow and lymphatic systems, and they are characterized by abnormal cell growth and impaired blood cell function. The rising incidence of these cancers, along with limited treatment options, particularly for relapsed or refractory cases, is contributing to the growing market demand for innovative treatments such as tecartus. Tecartus offers a novel approach to improving patient outcomes in hematologic cancer cases. For example, according to the American Cancer Society's January 2024 report, it is estimated that there will be approximately 6,550 new cases of acute lymphoblastic leukemia (ALL) in the United States in 2024, which is a slight increase from 6,540 cases in 2023. Given the rising prevalence of hematologic cancers, the demand for treatments such as tecartus is expected to continue growing.

The expansion of healthcare expenditure is also anticipated to support the growth of the tecartus market. Healthcare expenditure refers to the total spending on healthcare services, including medical treatments, hospital care, medications, and public health initiatives. The rise in healthcare spending is driven by factors such as advancements in medical technology, an increasing demand for healthcare services, and a greater focus on high-quality patient care, leading to more global investments. Increased healthcare expenditure enables the establishment of advanced treatment centers capable of delivering complex therapies such as CAR-T treatments, which include the manufacturing and administration processes needed for tecartus. For instance, according to the Centers for Medicare and Medicaid Services, US healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% increase seen in 2021. This growth in healthcare expenditure is likely to further propel the tecartus market.

A significant trend in the tecartus market is the expansion of CAR T-cell therapies to treat broader indications, including relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This trend is helping establish these therapies as reliable, effective, and innovative treatments in oncology. Tecartus, which is approved for use in adults with relapsed or refractory B-cell precursor ALL, has shown high remission rates and durable responses. For example, in September 2022, Kite Pharma, Inc. received approval from the European Commission for tecartus (brexucabtagene autoleucel) to treat adults aged 26 and older with relapsed or refractory B-cell precursor ALL. This approval was based on results from the ZUMA-3 study, which demonstrated that 71% of evaluable patients achieved complete remission or complete remission with incomplete hematological recovery, with a median overall survival of over two years, and nearly four years for responders. The safety profile was consistent with known data, with manageable instances of Grade 3+ cytokine release syndrome in 25% of patients and neurologic events in 32%.

The key company operating in the tecartus market is Gilead Sciences Inc.

North America was the largest region in the tecartus market in 2024. The regions covered in tecartus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tecartus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tecartus is a CAR-T cell therapy designed to treat specific blood cancers, including relapsed or refractory mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (ALL). It works by genetically modifying a patient's T-cells to target and eliminate cancer cells, offering a personalized and precise treatment approach.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Tecartus include mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and other hematologic cancers. MCL is a rare and aggressive type of non-Hodgkin lymphoma that affects the lymphatic system. Tecartus is used for patients with relapsed or refractory MCL to improve survival rates and alleviate symptoms. Distribution of the therapy is typically through hospitals and specialty pharmacies, catering to pediatric, adult, and geriatric patients.

The tecartus market consists of sales of autologous cell therapy (personalized treatment), infusion solution, cryopreserved formulation, and viral vectors for cell modification. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.